Skip to main content
Premium Trial:

Request an Annual Quote

Millipore's Q2 Profit Rises as Currency Hits Top Line

NEW YORK (GenomeWeb News) – Millipore reported after the close of the market Thursday that its second-quarter profit rose 5 percent, but the negative effects of currency translation resulted in a 1 percent decline in revenues year over year.

The Billerica, Mass.-based life sciences products firm reported total revenues of $408.6 million for the three-month period ended July 4, compared to revenues of $414.2 million for the second quarter of 2008. Excluding foreign currency translation, Millipore's revenues were up 5 percent.

The firm's Bioscience Division had revenues of $178.7 million compared to $184.4 million the year before, while its Bioprocess Division had revenues of $229.9 million versus $229.8 million.

"[O]ur Bioprocess Division sustained the recovery that it began earlier this year," said Martin Madaus, Chairman and CEO of Millipore, in a statement. "The growth of the division was driven by higher spending on our downstream bioprocessing products from biotechnology customers in North America and Asia. Our Bioscience Division performance was highlighted by strength in our flow cytometry business and by accelerating growth in Life Science product categories such as stem cell research and multiplex immunoassays."

Millipore's profit for the quarter was $41.6 million, or $.72 per share, up from $39.6 million, or $.69 per share, for the second quarter of 2008.

Its R&D spending increased to $29.1 million from $26.2 million, while its SG&A expenses declined to $130.7 million from $134.5 million.

Millipore finished the quarter with $146.6 million in cash and cash equivalents.

The company expects its full-year 2009 revenues to be between 2 percent and 3 percent higher than its 2008 revenues of $1.6 billion. It raised its non-GAAP EPS to a range of between $3.85 and $3.95 from its previous guidance of between $3.75 and $3.90.

Filed under

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.